Cognitive Effects of Stimulant, Guanfacine, and Combined Treatment in Child and Adolescent Attention-Deficit/Hyperactivity Disorder
Open accessAbstract
Objective Psychostimulants are partially effective in reducing cognitive dysfunction associated with attention-deficit/hyperactivity disorder (ADHD). Cognitive effects of guanfacine, an alternative treatment, are poorly understood. Given its distinct action on α2A receptors, guanfacine may have different or complementary effects relative to stimulants. This study tested stimulant and guanfacine monotherapies relative to combined treatment on cognitive functions important in ADHD. Method Children with ADHD (n = 182; aged 7-14 years) completed an 8-week, double blind, randomized, controlled trial with 3 arms: d-methylphenidate (DMPH), guanfacine (GUAN), or combination treatment with DMPH and GUAN (COMB). A nonclinical comparison group (n = 93) had baseline testing, and a subset was retested 8 weeks later (n = 38). Analyses examined treatment effects in 4 cognitive domains (working memory, response inhibition, reaction time, and reaction time variability) constructed from 20 variables. Results The ADHD group showed impaired working memory relative to the nonclinical comparison group (effect size = -0.53 SD unit). The treatments differed in effects on working memory but not other cognitive domains. Combination treatment improved working memory more than GUAN but was not significantly better than DMPH alone. Treatment did not fully normalize the initial deficit in ADHD relative to the comparison group. Conclusion Combined treatment with DMPH and GUAN yielded greater improvements in working memory than placebo or GUAN alone, but the combined treatment was not superior to DMPH alone and did not extend to other cognitive domains. Although GUAN may be a useful add-on treatment to psychostimulants, additional strategies appear to be necessary to achieve normalization of cognitive function in ADHD. Clinical trial registration information Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder; http://clinicaltrials.gov/; NCT00429273.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The study's findings extend evidence of no acute or chronic effects of guanfacine on cognitive performance in children and adults with ADHD.
“They also extend evidence of no acute or chronic effects of guanfacine on cognitive performance in children and adults with ADHD (39–42).”
From Differential effects of a single dose of Lisdexamfetamine and Guanfacine on cognitive function in children with ADHD (2025) · cites this paper as [39]
The Discussion reports no significant cognitive benefit from guanfacine alone or added to a stimulant, and the Methods describe an eight-week trial in children aged 7–14 with ADHD. This supports the chronic-treatment finding in children, but the study did not test acute treatment or adults with ADHD. The Discussion also notes cognitive enhancement after acute administration in non-clinical studies. Page numbers are unavailable in our copy. (LLM, conf=0.87)
Experimental — accuracy not yet measuredMost studies found no effects of guanfacine on cognition in people with ADHD.
“The majority of studies found no effects of guanfacine on cognition; eight weeks of guanfacine compared to placebo did not improve WM performance, response inhibition, MRT, or RTV in 182 children with ADHD (39); likewise, 45 days of guanfacine relative to placebo had no effect on RT, sustained attention, spatial WM, and visual-motor processing in 178 children with ADHD (40).”
From Differential effects of a single dose of Lisdexamfetamine and Guanfacine on cognitive function in children with ADHD (2025) · cites this paper as [39]
Guanfacine, while improving ADHD symptoms relative to placebo, may not be an optimal drug to improve specific attention measures.
“Together, this suggests that guanfacine, while improving ADHD symptoms relative to placebo (39–41, 43, 44), may not be an optimal drug to improve specific attention measures.”
From Differential effects of a single dose of Lisdexamfetamine and Guanfacine on cognitive function in children with ADHD (2025) · cites this paper as [39]
The study adds to the majority of previous studies showing either no or negative effects of guanfacine on cognition in children with ADHD.
“Nevertheless, our study adds to the majority of previous studies showing either no (39–42) or negative effects (43) of guanfacine on cognition in children with ADHD, with only a single very small numbered study in 17 adults with ADHD showing cognitive improvement in interference inhibition (44).”
From Differential effects of a single dose of Lisdexamfetamine and Guanfacine on cognitive function in children with ADHD (2025) · cites this paper as [39]
The study's findings are in line with the majority of previous negative findings of guanfacine effects on inhibitory measures.
“While this is in line with the majority of the previous negative findings of guanfacine effects on these measures (39, 41, 42), for lisdexamfetamine, some studies of longer-term use found improvement in inhibitory measures (34, 36) while others did not (38).”
From Differential effects of a single dose of Lisdexamfetamine and Guanfacine on cognitive function in children with ADHD (2025) · cites this paper as [39]
Out of six studies testing effects of mostly longer-term guanfacine effects on cognition, four reported sedative symptoms or fatigue while two other studies did not record or report them.
“Out of six studies testing effects of mostly longer-term guanfacine effects on cognition, four reported sedative symptoms (39, 40, 43) or fatigue (44) while two other studies did not record or report them (39, 42).”
From Differential effects of a single dose of Lisdexamfetamine and Guanfacine on cognitive function in children with ADHD (2025) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Willcutt, E. G., Doyle, A. E., Nigg, J. T., Faraone, S. V., & Pennington, B. F. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.02.006 · Cited by 3,568 · see citing works
MARTINUSSEN, R., HAYDEN, J., HOGG-JOHNSON, S., & TANNOCK, R. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000153228.72591.73 · Cited by 1,297 · see citing works
Barkley, R. A. (1997) · Psychological Bulletin · doi:10.1037//0033-2909.121.1.65 · Cited by 580 · see citing works
Fair, D. A., Bathula, D., Nikolas, M. A., & Nigg, J. T. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115365109 · Cited by 464 · see citing works
Rubia, K., Alegria, A. A., Cubillo, A. I., Smith, A. B., Brammer, M. J., & Radua, J. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.10.016 · Cited by 315 · see citing works
Martinussen, R., & Tannock, R. (2006) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803390500205700 · Cited by 270 · see citing works
Advokat, C. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.03.006 · Cited by 219 · see citing works
Tucha, O., Prell, S., Mecklinger, L., Bormann-Kischkel, C., Kübber, S., Linder, M., Walitza, S., & Lange, K. W. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0318-2 · Cited by 89 · see citing works
The effects of guanfacine on context processing abnormalities in schizotypal personality disorder
McClure, M. M., Barch, D. M., Romero, M. J., Minzenberg, M. J., Triebwasser, J., Harvey, P. D., & Siever, L. J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.034 · Cited by 70 · see citing works
Kollins, S. H., López, F. A., Vince, B. D., Turnbow, J. M., Farrand, K., Lyne, A., Wigal, S. B., & Roth, T. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0064 · Cited by 53 · see citing works
Flagged first, then by citations
Research works printed but not linked: 18
- [1]Barkley RA Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder Journal of clinical psychiatry 2002 63 10 15 12562056
- [2]Fayyad J De Graaf R Kessler R Cross–national prevalence and correlates of adult attention–deficit hyperactivity disorder The British Journal of Psychiatry 2007 190 5 402 409 17470954
- [9]Rhodes SM Coghill DR Matthews K Methylphenidate restores visual memory, but not working memory function in attention deficit-hyperkinetic disorder Psychopharmacology (Berl) 2004 9 175 3 319 330 15138760
- [11]Ramos BP Arnsten AF Adrenergic pharmacology and cognition: focus on the prefrontal cortex Pharmacol Ther 2007 3 113 3 523 536 17303246 PMC2151919
- [12]Avery RA Franowicz JS Studholme C van Dyck CH Arnsten AF The alpha-2A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task Neuropsychopharmacology 2000 9 23 3 240 249 10942848
- [13]Arnsten AF Cai JX Goldman-Rakic PS The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes J Neurosci 1988 11 8 11 4287 4298 2903226 PMC6569464
- [14]Jakala P Riekkinen M Sirvio J Koivisto E Riekkinen P Jr Clonidine, but not guanfacine, impairs choice reaction time performance in young healthy volunteers Neuropsychopharmacology 1999 10 21 4 495 502 10481832
- [15]Arnsten AF Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology CNS drugs 2009 23 1 33 41 19621976
- [16]Newcorn JH Stein MA Childress AC Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration J Am Acad Child Adolesc Psychiatry 2013 52 921 930 23972694
- [17]Wilens TE Bukstein O Brams M A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry 2012 1 51 1 74 85 e72 22176941
- [19]Schulz KP Clerkin SM Fan J Halperin JM Newcorn JH Guanfacine modulates the influence of emotional cues on prefrontal cortex activation for cognitive control Psychopharmacology 2013 226 2 261 271 23086020 PMC3567242
- [21]Bedard AC Schulz KP Krone B Neural mechanisms underlying the therapeutic actions of guanfacine treatment in youth with ADHD: a pilot fMRI study Psychiatry Res 2015 3 30 231 3 353 356 25659477
- [22]Congdon E Altshuler LL Mumford JA Neural activation during response inhibition in adult attention-deficit/hyperactivity disorder: Preliminary findings on the effects of medication and symptom severity Psychiatry Research: Neuroimaging 2014 222 1 17 28 24581734 PMC4009011
- [23]Arnsten AF Jin LE Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale The Yale journal of biology and medicine 2012 3 85 1 45 58 22461743 PMC3313539
- [25]Sander C Arns M Olbrich S Hegerl U EEG-vigilance and response to stimulants in paediatric patients with attention deficit/hyperactivity disorder Clin Neurophysiol 2010 9 121 9 1511 1518 20382071
- [27]Coghill DR Seth S Pedroso S Usala T Currie J Gagliano A Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis Biological psychiatry 2014 10 15 76 8 603 615 24231201
- [28]Sallee FR McGough J Wigal T Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial J Am Acad Child Adolesc Psychiatry 2009 2 48 2 155 165 19106767
- [29]Biederman J Melmed RD Patel A McBurnett K Donahue J Lyne A Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD CNS spectrums 2008 12 13 12 1047 1055 19179940
Cited by
Sorted by citations
Linking ADHD to the Neural Circuitry of Attention
Mueller, A., Hong, D. S., Shepard, S., & Moore, T. (2017) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2017.03.009 · Cited by 158 · see citing works
Michelini, G., Lenartowicz, A., Diaz-Fong, J. P., Bilder, R. M., McGough, J. J., McCracken, J. T., & Loo, S. K. (2023) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2022.06.017 · Cited by 12 · see citing works
Self-citationEl Masri, S., Kowalczyk, O. S., Chiu, T. H., Criaud, M., Lukito, S., Mazibuko, N., Salazar de Pablo, G., Perez Rodriguez, V., Makos, O., Lam, S.-L., et al. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1676472
- Authors
- Bilder, R. M., Loo, S. K., McGough, J. J., Whelan, F., Hellemann, G., Sugar, C., Del’Homme, M., Sturm, A., Cowen, J., Hanada, G., & McCracken, J. T.
- Affiliations
- University of California, Los Angeles (US)
- University of Michigan (US)
- Corresponding author
- Bilder, Robert M.
- ORCID
- Venue
- Journal of the American Academy of Child & Adolescent Psychiatry
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 55
- Issue
- 8
- Pages
- 667-673
- ISSN
- 0890-8567 (ISSN-L)
- PMC
- PMC4964604
- OpenAlex
- W2418067944
- Cited by
- 29
- References
- 10
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 4 · 2017: 2 · 2016: 2
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Mental Health (P50MH077248)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Social Sciences › Psychology › Neuropsychology and Physiological Psychology › Developmental and Educational Neuropsychology
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- attention deficit hyperactivity disorder, guanfacine, methylphenidate, psychostimulants, combination therapy, working memory, response inhibition, reaction time, reaction time variability, cognitive impairment, children and adolescents, alpha2A-adrenergic receptor
- MeSH terms
- Adolescent, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Methylphenidate, Guanfacine, Outcome Assessment, Health Care, Adrenergic alpha-2 Receptor Agonists, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
